BT Group Transforms its Business Approach with a Cloud Core Network from Juniper Networks to Enable New Services at Exceptional Scale and Quality Globally
19.7.2023 11:00:00 EEST | Business Wire | Press release
Juniper Networks (NYSE:JNPR), a leader in secure, AI-driven networks, today announced it is supporting BT Group’s ongoing transformation journey towards a highly scalable, automated and robust cloud core infrastructure for business and consumer customers. BT Network Cloud supports diverse network applications across broadband, fixed, mobile and other mission-critical services on a single platform, using Juniper Networks’ high-performance cloud-native solutions and professional services.
With this strategic deployment, BT Network Cloud has now scaled to accommodate multiple key network-centric applications, such as mobile voice and data, broadband authentication and IP voice calls for tens of millions of customers without extra overhead costs. An innovative global technology footprint from Juniper, including infrastructure consolidation and virtualization, along with improved hardware density and power efficiency, reduces space and power requirements in support of a more sustainable infrastructure.
BT Simplifies and Improves Service Quality with Agile Network Cloud
BT Network Cloud enables applications that underpin BT Group's U.K. consumer and business network services. Juniper’s high-performance, high-availability fabric for BT Network Cloud provides extreme robustness and high performance for BT Group’s core applications across a widely distributed user base deployed at multiple locations across the U.K. Moving from dedicated compute platforms for each application to a shared infrastructure conserves and optimizes resources leading to better resource utilization and significantly lower environmental impact.
The provider’s network cloud optimizes service quality and streamlines operational deployment and management of core applications, which enables innovation and agility in delivering new services to market such as enhanced 5G services.
5G Roll Out and Scale to Meet Digital Demand
The introduction of 5G created a unique opportunity for BT Group to transform its core network to ensure it was well-positioned to offer a dynamic range of new services to customers at unprecedented scale. BT Group chose to build a network cloud to provide a common shared platform for core applications, which operate its broadband, fixed and mobile services. BT Group has migrated tens of millions of mobile subscribers and successfully deployed all its mobile application infrastructure on its network cloud.
The goal of the multiyear journey at BT Group was to deploy a state-of-the-art container-based fixed, broadband and mobile core that will boost business agility, operational efficiency, sustainability and meet security compliance.
News Highlights:
-BT uses Juniper for open, software-defined networking (SDN), switching and firewall solutions for its network cloud. The service provider uses Juniper’s SDN platform to automate the creation and management of its OpenStack-based telco cloud. The platform provides hybrid SDN orchestration and centralized control of virtual switching, routing and security. BT is running cloud-native containerized applications and optimizing costs using OpenStack.
-Juniper QFX Series Switches provide the high-performance, high-availability fabric needed to support the BT Network Cloud which has rapidly become the largest container-based cloud infrastructure in the world, and is still growing.
-BT’s cloud-native platform is deployed at multiple locations across the U.K. to form a distributed architecture designed to scale seamlessly alongside demand and to provide services closer to the end user than with traditional, more centralized deployments.
-Juniper collaborated with BT to deliver high-performance, high-availability fabric for BT Network Cloud. BT’s data centers contain over 1,000 Juniper QFX Series Switches and 2,000 Juniper vRouters. The switches connect all mission-critical application servers to the core network. The SDN platform is deployed on the servers to provide virtualized routing capability to connect workloads across BT’s network securely.
-Juniper vSRX Virtual Firewalls protect and secure the data center traffic. vSRX provides a network address translation capability which was not possible for one of BT’s application providers to deliver in software.
-BT Group selected Juniper for its engineering excellence and ability to provide an end-to-end network solution including hardware, software and tools that can integrate reliably with the complete cloud stack.
-By leveraging Juniper’s professional services, BT has successfully completed the project on time and ensured that the challenging service level, availability and performance targets of BT’s applications are met.
Supporting Quotes:
“Telecoms services have become central to business and consumer lives and as the U.K.’s national network provider, BT Group has a particular responsibility to lead from the front to deliver the cloud-native, sustainable digital services of the future. Our work with partners such as Juniper is helping to ensure that our critical infrastructure, network and services are agile, secure and resilient for the long term. Our millions of customers can remain confident in the experience-led integrity of the everyday and exceptional digital services on which they rely.”
- Howard Watson, Chief Security and Networks Officer, BT Group
“We are delighted that Juniper’s cloud-native networking solutions and comprehensive professional services were selected as the cornerstone of the BT Network Cloud. BT can respond to the demands of the next chapter of digital transformation at scale whilst leveraging the power of the network to enable new digital services for BT’s customers, fully supported by a cloud-native architecture enabling security, automation, scale and agility.”
- Raj Yavatkar, Chief Technology Officer, Juniper Networks
Additional Resources
BT: Success Story
About Juniper Networks
Juniper Networks is dedicated to dramatically simplifying network operations and driving superior experiences for end users. Our solutions deliver industry-leading insight, automation, security and AI to drive real business results. We believe that powering connections will bring us closer together while empowering us all to solve the world’s greatest challenges of well-being, sustainability and equality. Additional information can be found at Juniper Networks (www.juniper.net) or connect with Juniper on Twitter, LinkedIn and Facebook.
Juniper Networks, the Juniper Networks logo, Juniper, Junos, and other trademarks listed here are registered trademarks of Juniper Networks, Inc. and/or its affiliates in the United States and other countries. Other names may be trademarks of their respective owners.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230719046766/en/
Contact information
Media Relations:
Pelin Murphy
Juniper Networks
pelin@juniper.net
+44 (0) 1372 385 686
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Announces US FDA Approval for Label Extensions of ALYFTREK ® and TRIKAFTA ® , Expanding Availability of These Medicines to ~95% of All People With CF in the United States1.4.2026 14:30:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) has approved expanded use of ALYFTREK® (vanzacaftor/tezacaftor/ivacaftor) for the treatment of people with cystic fibrosis (CF) ages 6 and older with a variant in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that is either responsive based on clinical and/or in vitro data or results in production of CFTR protein. Additionally, the U.S. FDA has also expanded the indication statement for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in patients ages 2 and older. This label expansion was supported by clinical and/or in vitro data from 564 variants demonstrating response to ALYFTREK and 521 variants demonstrating response to TRIKAFTA. As such, approximately 800 more people with a clinical diagnosis of CF in the U.S. are now eligible for a medicine that treats the underlying cause of their disease for the first time. This extension means approxim
Agenus Announces First Patient Enrolled in Global Phase 3 BATTMAN Trial of BOT+BAL Immunotherapy Combination in MSS or pMMR Metastatic Colorectal Cancer1.4.2026 14:30:00 EEST | Press release
Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that the first patient has been enrolled in the landmark global phase 3 BATTMAN (CO.33) trial (NCT07152821). This study is evaluating Agenus’ immunotherapy combination of botensilimab (BOT) plus balstilimab (BAL) versus best supportive care in patients with refractory, unresectable microsatellite stable (MSS)/mismatch repair proficient (pMMR) metastatic colorectal cancer (mCRC), a population long considered resistant to immunotherapy. This study is being conducted as a cooperative group trial led by the Canadian Cancer Trials Group (CCTG) from Canada and run across Canada, France, Australia and New Zealand. More than 100 sites will participate across the academic cooperative networks of CCTG, GI Cancer Trials in Australia and France’s Partenariat de Recherche en Oncologie Digestive (PRODIGE) consortium (including Unicancer, GERCOR and FFCD). The BATTMAN (CO.33) trial serves as the registrational-enablin
Klarna Agrees to $1.7 Billion Transaction Supporting up to $40B+ of Lending1.4.2026 14:19:00 EEST | Press release
Klarna, the global digital bank and flexible payments provider, has entered into a new capital efficiency transaction in the form of a Significant Risk Transfer (SRT), covering $1.7 billion-worth of Euro denominated loans and freeing up capital to support continued growth. Klarna has entered into a three-year agreement with a consortium led by Värde Partners. This is Klarna's sixth SRT transaction and improves how effectively Klarna deploys its capital on a global basis. "Our banking license is one of our biggest competitive advantages," said Niclas Neglén, Klarna's Chief Financial Officer. "This is our largest and most efficient SRT transaction to date. These transactions allow us to maximize every unit of capital to support our continued momentum." The transaction follows Klarna’s recently announced $2 billion facility supporting $17B of US Financing expansion. About Klarna Klarna is a global digital bank and flexible payments provider. With over 118 million global active Klarna user
Americhem Launches nDryve™: PFAS-Free In-Melt Technology Platform for Functional Fibers1.4.2026 14:00:00 EEST | Press release
Americhem, Inc., a global polymer solutions provider, today announced the launch of nDryve™, a PFAS-free, in-melt surface-modifying technology platform designed to deliver durable multi-fluid repellency against alcohol and other low-surface-energy fluids in fiber systems. As global regulations accelerate the phase-out of per- and polyfluoroalkyl substances (PFAS), manufacturers are under increasing pressure to maintain barrier performance without fluorinated chemistries. nDryve™ was developed to address this shift, offering a PFAS-free, in-melt alternative to conventional surface applied treatments. Engineered for Performance Without PFAS Often referred to as “forever chemicals,” PFAS have come under heightened regulatory scrutiny due to their persistence and potential environmental and health impacts. nDryve™ integrates directly into the polymer during melt processing, embedding surface-modifying functionality within the fiber matrix rather than relying on removable finishes. By engin
Biocytogen and Sihuan Pharmaceutical Announce Strategic Partnership in Weight Loss and Beyond1.4.2026 14:00:00 EEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced a strategic partnership with Sihuan Pharmaceutical Holdings Group Ltd. (Sihuan Pharmaceutical; HKEX: 00460). Under the agreement, both parties will combine Biocytogen’s leading fully human antibody discovery platform with Sihuan Pharmaceutical’s extensive capabilities in drug development, manufacturing, and commercialization. The collaboration will focus on advancing innovative therapies across multiple disease areas, including weight loss, leveraging complementary strengths to drive synergies and establish a long-term strategic partnership. Sihuan Pharmaceutical highly values the strength of Biocytogen’s technology platforms. In this collaboration, Biocytogen will leverage its integrated platforms, including proprietary target-humanized mouse models and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
